What I have: ALT · mazdutide.
I am trying to build something sustainable rather than something thorough that I will abandon.
I have already decided the broad direction; this is about the specifics.
What would you do, and what would make you change course?
The short version: a small, well-chosen panel with a baseline beats a large one without.
Repeat before you react. A single abnormal value has a substantial probability of being within the combined biological and analytical variation of a normal one.
Haemolysis in the sample raises potassium and several enzymes spuriously. If a result is bizarre, ask whether the sample was flagged before building a theory on it.
External quality assurance schemes document between-laboratory differences on common analytes that routinely exceed the size of clinically interesting changes.
Same laboratory, same time, same fasting state, or the comparison is not a comparison.
Aggregated, published test results and vendor ratings built from submitted batches. Methodology stated, dataset browsable, no listing fees.
Browse resultsStandardise the conditions — same time of day, same fasting state, same laboratory — or you are measuring the conditions rather than yourself.
Same laboratory, same method, same time of day, same fasting state. Between-laboratory differences on several common analytes are larger than the changes people are trying to detect.
Keep the reports rather than the numbers. Units, reference intervals and methods all vary, and a bare number two years later is not comparable to anything.
Nothing here is medical advice. If something is out of range and you do not know why, that is a consultation rather than a research project.
One out-of-range value on a twenty-analyte panel is expected. Two on a repeat is a finding.
Start with a baseline. A result taken before anything started converts most later ambiguity into a simple comparison, and it cannot be obtained retrospectively.
Timing matters per analyte: cortisol and testosterone are diurnal, triglycerides are postprandial, and creatinine responds to hydration and to recent training. Fixing the conditions removes most of the noise.
Concretely, a twenty-analyte panel run on a healthy person will produce, on average, one out-of-range result purely from how reference intervals are constructed. That is arithmetic rather than pathology.
Decide the action for each result before you order the test.
The honest position is that most people order too many analytes and too few time points, when the reverse would be more informative.
Delta checks — comparing against your own previous value — are far more sensitive than comparing against a population interval, which is the argument for keeping a series rather than a snapshot.
Research-use compounds are not approved for human use, and no panel makes that safer.
Baseline first, then a repeat under identical conditions. Everything else is secondary.
Answering this needs to distinguish screening from monitoring. A screening panel looks for the unexpected; a monitoring panel tracks something you already have a reason to watch.
A sensible core for this population is a full blood count, renal function with electrolytes, liver enzymes with bilirubin, a fasting lipid panel with apolipoprotein B, HbA1c and thyroid-stimulating hormone.
Pre-analytical factors — posture, tourniquet time, fasting, sample handling — are the largest source of error in routine biochemistry, well ahead of the analysis itself.
Keep the full report, not the number. You will need the units and the interval later.
edited 29 Nov 2025 by Dr_Idris_Coulibaly — corrected a unit error in the worked example
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.